Since CD133+CXCR4+ endometrial cancer cells were shown to possess more significant proliferation, clonogenic, tumourigenic, and chemoresistance abilities (17), we also analysed the proportion of these double positive cells in primary cell culture established from patient’s tumour sample diagnosed to be type I endometrial cancer and in other patient’s tumour sample diagnosed to be type 2 endometrial cancer (Fig. 2A & 2B). This evidence concerns the gene PROM1 and endometrial cancer.